Contineum Therapeutics (CTNM) Gains from Investment Securities (2023 - 2024)
Contineum Therapeutics (CTNM) posted quarterly Gains from Investment Securities of -$1000.0 for Q4 2024, up 66.67% year-over-year from -$600.0 in Q1 2024, and up 90.91% quarter-over-quarter from -$11000.0 in Q2 2024.
Powered by 
Analysis
Contineum Therapeutics (CTNM) Gains from Investment Securities (2023 - 2024) Analysis & Trends
Contineum Therapeutics' Gains from Investment Securities history runs 2 years deep, the most recent figure standing at -$1000.0 for Q4 2024.
- In Q4 2024, Gains from Investment Securities rose 66.67% year-over-year to -$1000.0; the TTM figure through Sep 2025 stood at -$1000.0 (down 100.97% YoY), while the FY2024 annual figure was $106000.0, up 2220.0% from the prior year.
- Gains from Investment Securities for Q4 2024 stood at -$1000.0, up from -$11000.0 in the prior quarter.
- The five-year high for Gains from Investment Securities was $117000.0 in Q1 2024, with the low at -$11000.0 in Q2 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Contineum Therapeutics | 628.71 Mn | 628.71 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | -1,000.00 |
| Jun 30, 2024 | -11,000.00 |
| Mar 31, 2024 | 117,000.00 |
| Dec 31, 2023 | -3,000.00 |
| Jun 30, 2023 | -2,000.00 |